Recent progress in carcinogenesis, progression and therapy of breast cancer: the 20th Hiroshima Cancer Seminar--the 4th Three Universities' Consortium International Symposium, October 2010: 31 October 2010, International Conference Center Hiroshima.

Abstract	The 20th Hiroshima Cancer seminar focused upon breast cancer research and treatment particularly on the mechanism of tumorigenesis and drug resistance and development of novel therapeutics. Several molecules such as retinoblastoma and p16 were raised as key factors in tumorigenesis and invasiveness. Estrogen-related pathways seem to be closely involved in the process. For the tumor lacking hormone receptor and human epidermal growth factor 2, some other mechanisms could be responsible. It seems that MicroRNA 22 directing some putative targets such as SIRT1, Sp1 and CDK6 plays a crucial role in breast tumor growth and metastasis. In addition, ribophorin and the associated molecules might be engaged in breast cancer stemness. Obviously, these molecules provide potential for therapeutic targets. It was also discussed about new drug development such as anti-human epidermal growth factor 2 therapy, anti-angiogenesis, pro-tumor aspects of anti-cancer therapy and application of circulating markers for monitoring, imaging and health-care system. Furthermore, we discussed risk factors, prevention and screening to reduce invasive cancers as well. Throughout the conference, panelists and attendee indicated the importance of translational research and biomarker exploration in order to realize efficient and individualized therapy for breast cancer.
Authors	Masakazu Toi, Wataru Yasui, Hisao Ito, Eiichi Tahara
Journal	Japanese journal of clinical oncology (Jpn J Clin Oncol) Vol. 41 Issue 7 Pg. 924-30 (Jul 2011) ISSN: 1465-3621 [Electronic] England
PMID	21565925 (Publication Type: Congress)
Chemical References	Angiogenesis Inhibitors Antineoplastic Agents Biomarkers, Tumor CDKN2A protein, human Cyclin-Dependent Kinase Inhibitor p16 Estrogens MIRN22 microRNA, human Membrane Proteins MicroRNAs Neoplasm Proteins Proteasome Inhibitors Receptors, Immunologic ribophorin trophoblastic beta 1-glycoprotein receptor, human Fluorodeoxyglucose F18 Hexosyltransferases RPN2 protein, human ERBB2 protein, human Receptor, ErbB-2 CDK6 protein, human Cyclin-Dependent Kinase 6 Proteasome Endopeptidase Complex SIRT1 protein, human Sirtuin 1
Topics	Angiogenesis Inhibitors (pharmacology) Antineoplastic Agents (economics, pharmacology, therapeutic use) Biomarkers, Tumor (blood, metabolism) Breast Neoplasms (blood, metabolism, pathology, therapy) Cell Transformation, Neoplastic (drug effects) Cost-Benefit Analysis Cyclin-Dependent Kinase 6 (metabolism) Cyclin-Dependent Kinase Inhibitor p16 Disease Progression Drug Resistance, Neoplasm Estrogens (metabolism) Female Fluorodeoxyglucose F18 Hexosyltransferases Humans Insurance Coverage International Cooperation Membrane Proteins (metabolism) MicroRNAs (metabolism) Molecular Targeted Therapy (methods) Neoplasm Proteins (drug effects, genetics, metabolism) Positron-Emission Tomography (methods) Proteasome Endopeptidase Complex Proteasome Inhibitors Receptor, ErbB-2 (metabolism) Receptors, Immunologic (metabolism) Signal Transduction (drug effects) Sirtuin 1 (metabolism) Universities

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!